gold nanoparticles  (ATCC)

Journal: bioRxiv

Article Title: Ultra-long stable biomimetic nanoparticle Click-ed-to-cancer membrane for anti-cancer treatment

doi: 10.64898/2026.04.19.719453

Figure Lengend Snippet: (a) UV-Vis spectrum of the biomimetic gold nanoparticles; (b) DLS; (c) Z-potential; (d) TEM of the biomimetic gold nanoparticles showing protein corona around nanoparticles (red arrow); (e) FT-IR of the biomimetic gold nanoparticles; (f) Raman 2D mapping of the biomimetic gold nanoparticles on FFPE slides of adenoid cystic carcinoma of salivary gland (NBP2-30299, Novus Biologicals), showing comparison of Raman signal intensity of sample (Click chemistry activated gold nanoparticles) and control (bare gold nanoparticles). Scale 100 µm. (g) Raman 3D mapping (30 x 25 x 4 µm), red dots indicate regions of high Raman intensity at ~1010 cm −1 , blue area indicates weak Raman signal form the tissue in 3D Raman mapping. Scale 20 µm.

Article Snippet: Upon sub-cellular fractionation, membranes of (i) H1573 cells (lung adenocarcinoma) encapsulated gold nanoparticles incubated in RPMI 1640 Medium (R8758-500 ML), 10% FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); (ii) OVCA432 cells (high-grade serous epithelial ovarian cancer) encapsulated gold nanoparticles incubated in Medium 199 (M4530-500ML, Merc Life Science Pty Ltd), MCDB 105 Medium (M6395-1L, Merc Life Science Pty Ltd), 1% Penicillin/Streptomycin solution (G255, abm); (iii) CaCO2 [HTB-37, ATCC] (Colorectal Cancer) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco); (iv) UM-HACC-2A cells (adenoid cystic carcinoma) (T8326, abm) encapsulated gold nanoparticles incubated in optimized salivary gland medium consisted of PriGroIII (TM003, abm), 10% fetal bovine serum (A56695-01, gibco), 2 mM L-glutamine (G275, abm), 0.4 μg/mL hydrocortisone (H0135-1MG, Sigma Aldrich), 20 ng/mL recombinant human epidermal growth factor (Z100139. abm), 5 μg/mL recombinant human insulin (Z101065, abm), 1% Penicillin/Streptomycin solution (G255, abm); (v) A-375 cells (malignant melanoma) (CRL-1619, ATCC) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); (vi) SCC9 cells (oral cancer) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); (vii) CW1474 cell line (CRL-3529, ATCC) (esophageal adenocarcinoma) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); and (viii) MCF7 [HTB-22, ATCC] (Breast Cancer) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); at 4 °C for 12-months.

Techniques: Comparison, Control

Journal: bioRxiv

Article Title: Ultra-long stable biomimetic nanoparticle Click-ed-to-cancer membrane for anti-cancer treatment

doi: 10.64898/2026.04.19.719453

Figure Lengend Snippet: Red arrow indicates membrane protein corona around the biomimetic gold nanoparticles of (a) lung adenocarcinoma, (b) malignant melanoma, (c) high-grade serous epithelial ovarian cancer, (d) colorectal cancer, (e) oral cancer, (f) esophageal adenocarcinoma, (g) adenoid cystic carcinoma of salivary gland, and (h) breast cancer, at magnification 80,000X, Scale 0.1 µm.

Article Snippet: Upon sub-cellular fractionation, membranes of (i) H1573 cells (lung adenocarcinoma) encapsulated gold nanoparticles incubated in RPMI 1640 Medium (R8758-500 ML), 10% FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); (ii) OVCA432 cells (high-grade serous epithelial ovarian cancer) encapsulated gold nanoparticles incubated in Medium 199 (M4530-500ML, Merc Life Science Pty Ltd), MCDB 105 Medium (M6395-1L, Merc Life Science Pty Ltd), 1% Penicillin/Streptomycin solution (G255, abm); (iii) CaCO2 [HTB-37, ATCC] (Colorectal Cancer) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco); (iv) UM-HACC-2A cells (adenoid cystic carcinoma) (T8326, abm) encapsulated gold nanoparticles incubated in optimized salivary gland medium consisted of PriGroIII (TM003, abm), 10% fetal bovine serum (A56695-01, gibco), 2 mM L-glutamine (G275, abm), 0.4 μg/mL hydrocortisone (H0135-1MG, Sigma Aldrich), 20 ng/mL recombinant human epidermal growth factor (Z100139. abm), 5 μg/mL recombinant human insulin (Z101065, abm), 1% Penicillin/Streptomycin solution (G255, abm); (v) A-375 cells (malignant melanoma) (CRL-1619, ATCC) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); (vi) SCC9 cells (oral cancer) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); (vii) CW1474 cell line (CRL-3529, ATCC) (esophageal adenocarcinoma) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); and (viii) MCF7 [HTB-22, ATCC] (Breast Cancer) encapsulated gold nanoparticles incubated in High-glucose Dulbecco’s modification of Eagle medium (DMEM) (D5796-500ML, Thermo Fisher Scientific), FBS (A56695-01, gibco), 1% Penicillin/Streptomycin solution (G255, abm); at 4 °C for 12-months.

Techniques: Membrane

Journal: Nature Communications

Article Title: Using rotational integration of oblique interferometric scattering to track axial spatiotemporal responses of tubular membrane protrusions

doi: 10.1038/s41467-026-72302-1

Figure Lengend Snippet: a i, Raw iSCAT image of 40 nm gold nanoparticles with 500 ms exposure time. Gold nanoparticles were dried thus adhered to the inner glass bottom, then PBS for 1:20 dilution to the initial storage liquid of nanoparticles. ii, Manually selected background pattern from PBS-only control dish under the same exposure time. iii, Final iSCAT image after post-processing of background subtraction. The dashed rectangle region highlights the blurring pattern in iSCAT, but is well-distinguished by RO-iSCAT. b i, RO-iSCAT images from different incoming azimuths without integration. ii, Final RO-iSCAT image with time-integrating during rotational scanning. c i, Intensity profile of raw image, background and the final result after subtraction, along the dashed line in magnified image cropped from ( a ) iii, the orange and green scatters are labelled by the left y axis while the blue curve is by right y axis. ii, Intensity profile of image at azimuth position of 0°, 90°, 180°, 270° and final integrated result along the dashed line in magnified image cropped from ( b ) ii, the blue curve is by right y axis while the scatters in other colours are labelled by left y axis. d Lateral and axial patterns captured from 40 nm gold particles, 100 nm polystyrene spheres and KPC extracellular vesicles, individually without rotational integration (top) and with rotational integration (bottom) configuration. Red dashed lines mark the region where xz cross-sections are shown. e Without rotational integration (top) against rotational integration (bottom) modality of CAF cells seeded with 40 nm nanoparticles. The magnifications highlight the tracking of membrane protrusions and nanoparticles. Scale bars : ( a , b , d ) 1 μm, ( c ) 500 nm, ( e ) 10 μm, insets in ( e ) 1 μm. Data shown are representative samples from 5 experiments for ( a , b , d ) and 3 experiments for ( e ).

Article Snippet: 40 nm gold nanoparticles were dried onto a glass bottom dishes (#1 coverslip thickness, CellVis) for 1 hr as described above.

Techniques: Control, Membrane

Journal: mAbs

Article Title: Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties

doi: 10.1080/19420862.2026.2663641

Figure Lengend Snippet: Overview of approach for predicting antibodies with low self-association and favorable biophysical properties at high concentration. First, antibody self-association is measured using charge-stabilized self-interaction nanoparticle spectroscopy (CS-SINS) at ultra-dilute concentrations (0.01 mg/mL mAb) in different formulation conditions. Next, antibody structural models are generated, and molecular features are extracted and analyzed. These features are also used to generate classifier or regressor models for predicting antibodies with high or low CS-SINS scores. Finally, the antibody self-association predictions were used to identify antibodies with low viscosity or high recovery after concentration.

Article Snippet: Next, 1.2 mL of 20 nm gold nanoparticles (Ted Pella, 15,705) was concentrated to 100 μL by centrifugation at 21,300 xg for 6 min using 1.5 mL centrifuge tubes (USA Scientific, 1615–5500).

Techniques: Concentration Assay, Spectroscopy, Formulation, Generated, Viscosity